Network pharmacological analysis and in vivo experimental verification of Shen-ling Baizhu San in treatment of ulcerative colitis
10.16303/j.cnki.1005-4545.2025.04.20
- VernacularTitle:参苓白术散治疗溃疡性结肠炎的网络药理学分析及体内试验验证
- Author:
Jianing WANG
1
;
Chenying WANG
;
Shicheng BI
;
Qi MA
Author Information
1. 西南大学动物医学院 重庆 402460
- Publication Type:Journal Article
- Keywords:
network pharmacology;
Shenling Baizhu powder;
ulcerative colitis;
molecular docking;
BALB/c mice
- From:
Chinese Journal of Veterinary Science
2025;45(4):770-781
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the mechanism of Shenling Baizhu San(SLBZS)in the treat-ment of ulcerative colitis(UC)based on systematic network pharmacology and in vivo experimen-tal verification.Systematic network pharmacology was used to predict the core targets and key pathways of the SLBZS in the treatment of UC,it was further validated in UC model of BALB/c mice which were established with DSS[3.5％(w/v)],and SLBZS was given orally for treatment at the same time.Network analysis of SLBZS identified 153 active compounds and 68 compound-re-lated targets correlated with UC.Additionally,5 core active compounds were obtained,such as rob-inin,luteolin,kaempferol,quercetin,denudatin B.Most of the compounds have proven to have phar-macological activities.Based on PPI network and pathway enrichment studies,SLBZS may exert anti-inflammatory,immunological regulation,and participate in the process of apoptosis through regulating IL6,TNF,IL1B,PTGS2,TP53,STAT3,CASP3,IL10,CXCL8,IL2,PPARG,PTPRC,IFNG,MTOR,MMP9,so as to affect cell differentiation,TNF signaling,cancer signaling,IL-17 signaling,NF-Kappa B signaling of Th17 cell.The results of in vivo animal experiments showed that SBP could significantly improve the clinical symptoms and colonic pathological changes of UC mice,regulate the abnormal changes of blood routine indexes,increase the serum inflammatory factors IL-4 and IL-10,and reduce the contents of IL-6,IL-2,IL-1β and TNF-α.These results indi-cates that SBP can treat ulcerative colitis through TNF signaling pathway and NF-Kappa B signa-ling pathway.
